LAQUINIMOD: A NEW ORAL IMMUNOMODULATOR FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
New Players in MS
October 30, 2010
The copyright for all illustrations and pictures has been heeded by all authors to the best of their knowledge. If you feel your copyright has been infringed in any way or if you have any questions, do contact us by clicking on this link, please.
|Congress:||The 4th World Congress on Controversies in Neurology (CONy)|
Laquinimod is a novel oral, once-daily immunomodulator which is currently in advanced stages of clinical development for the treatment of relapsing-remitting multiple sclerosis (RRMS). Laquinimod was demonstrated to be effective in various experimental autoimmune encephalomyelitis models. The ameliorating activity of laquinimod is mediated by various effects, modulating the immune system away from its typical disease properties. These include effects seen on cytokine profile, leukocytes infiltration to inflamed tissues and antigen presentation. Neuroprotective effects were demonstrated by reduced spinal cord demyelination and axonal loss in MS animal models.
|Category:||Inflammation; Cytokines; Neurology; Multiple Sclerosis; treatment;|